Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005077 | 1.00 | TSHR (0.36) | TSHRGRIA2KCNA3KCNN4KCNA5 | |
| SCHEMBL20207409 | 0.96 | TSHR (0.36) | TSHRGRIA2KCNA3KCNN4KCNA5 | |
| SCHEMBL6020194 | 0.94 | MLYCD (0.37) | TSHRGRIA2SLC16A3SLC16A1USP2 | |
| SCHEMBL7602428 | 0.87 | TSHR (0.40) | TSHRUSP2HSD17B10CRHR1ALDH1A1 | |
| SCHEMBL20207415 | 0.87 | TSHR (0.40) | TSHRUSP2HSD17B10CRHR1ALDH1A1 | |
| SCHEMBL14947359 | 0.84 | CYP2C19 (0.40) | TSHRGRIA2HSD17B10ALDH1A1 | |
| SCHEMBL151638 | 0.77 | TSHR (0.47) | TSHRKCNA3KCNN4KCNA5USP2 | |
| SCHEMBL6206075 | 0.77 | KDM4E (0.36) | HSD17B10ALDH1A1HPGD | |
| SCHEMBL13900261 | 0.77 | KCNN4 (0.32) | KCNN4KCNA5 | |
| SCHEMBL21173008 | 0.75 | MAPT (0.35) | TSHRGRIA2SLC16A3SLC16A1CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249461-A1 | TRIARYLAMINE DERIVATIVE | MASAKI TOMOHITO | 2010-09-30 | — | — | US | disclosed |
| US-20080255388-A1 | TRIARYLAMINE DERIVATIVE | FUJIFILM CORPORATION (JP) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249461-A1 | TRIARYLAMINE DERIVATIVE | ADRB3, YWHAZ, DRD2 | TSHR 84/4885GRIA2 467/4885KCNA3 910/4885 |
| US-20080255388-A1 | TRIARYLAMINE DERIVATIVE | GPR35, NR1I2, GPR55 | TSHR 114/4885GRIA2 386/4885KCNA3 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.